Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

@article{Hanauer2002MaintenanceIF,
  title={Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial},
  author={Stephen Hanauer and Brian G. Feagan and Gary R. Lichtenstein and Lloyd F. Mayer and S Schreiber and J F Colombel and Daniel Rachmilewitz and Douglas C Wolf and Allan D. Olson and Weihang Bao and Paul Rutgeerts},
  journal={The Lancet},
  year={2002},
  volume={359},
  pages={1541-1549}
}

Figures and Tables from this paper

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease.
  • S. Hanauer, C. Wagner, P. Rutgeerts
  • Medicine, Biology
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2004
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
TLDR
The scheduled infliximab groups, particularly the 10 mg/kg group, had better CDAI and Inflammatory Bowel Disease Questionnaire (IBDQ) responses than those in the episodic group.
Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.
TLDR
The combination of infliximab and methotrexate, although safe, was no more effective than inflIXimab alone in patients with CD receiving treatment with prednisone.
Infliximab maintenance therapy for fistulizing Crohn's disease.
TLDR
Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
TLDR
Pediatric patients responding to an induction regimen of infliximab were more likely to be in clinical response and remission at week 54 without dose adjustment when their maintenance therapy was given every 8 weeks rather than every 12 weeks.
Retrieval of Serum Infliximab Level by Shortening the Maintenance Infusion Interval Is Correlated with Clinical Efficacy in Crohn's Disease
TLDR
A treatment strategy with an option of shortening the dosing interval of infliximab retrieves its trough level and may be useful for maintaining its efficacy and a correlation between clinical efficacy and serum trough level was found.
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
TLDR
Adalimumab was well-tolerated, with a safety profile consistent with previous experience with the drug, and was significantly more effective than placebo in maintaining remission in moderate to severe CD through 56 weeks.
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial
TLDR
Elective switching from infliximab to adalimumab is associated with loss of tolerance and loss of efficacy within 1 year, and adherence to the first anti-TNF agent is recommended.
Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial
TLDR
Doubling the infliximab dose safely led to remission in patients with Crohn's disease with LOR to 5 mg/kg treatment, and remission was associated with pre-escalation levels of inflIXimab, interleukin 6, and albumin.
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
  • W. Sandborn, M. Abreu, P. Rutgeerts
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2010
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
Infliximab in Crohn's disease: first anniversary clinical experience
TLDR
Clinical experience with infliximab closely parallels the results of the controlled clinical trials, and includes steroid-sparing effects.
Long term safety of infliximab.
  • T. Schaible
  • Medicine
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • 2000
TLDR
While infections were reported more frequently overall in the patients given infliximab, there was no increased risk of serious infections and drug-induced lupus was seen in less than 1%, with these cases resolving upon discontinuation of the drug.
Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.
TLDR
In a group of patients with chronically active Crohn's disease, methotrexate was more effective than placebo in improving symptoms and reducing requirements for prednisone.
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients
TLDR
Clinical outcome and adverse events in the first 100 patients with refractory inflammatory and/or fistulizing Crohn's disease treated with inflIXimab at the Mayo Clinic provide additional evidence that infliximab is safe and beneficial in clinical practice for refractors' disease.
Maintenance therapy in Crohn's disease.
  • H. Steinhart
  • Medicine
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • 2000
TLDR
A chimeric mouse-human antibody to tumour necrosis factor (infliximab) has been shown to induce clinical remission and endoscopic improvement in patients with moderately active Crohn's disease refractory to other therapies.
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.
TLDR
At 1 year, 32% of patients with Crohn's disease and 48% with ulcerative colitis are corticosteroid free without operation.
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
TLDR
A 12-week multicenter, double-blind, placebo-controlled trial of cA2 in 108 patients with moderate-to-severe Crohn's disease that was resistant to treatment, finding clinical response, the primary end point, was a reduction of 70 or more points in the score on theCrohn's Disease Activity Index at four weeks.
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
TLDR
Multiple infusions of cA2 were effective and well tolerated, with the best results occurring at 3 and 10 mg/kg either alone or in combination with MTX in approximately 60% of patients with active RA despite therapy with low-dose MTX.
...
1
2
3
4
...